Foghorn Therapeutics (FHTX) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free FHTX Stock Alerts $5.21 +0.05 (+0.97%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePetri Dish: Non-viral vector startup launch; Foghorn’s new CFObizjournals.com - April 18 at 7:13 AMFoghorn Therapeutics Taps Kristian Humer as Finance Chiefmarketwatch.com - April 16 at 12:40 PMFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officerglobenewswire.com - April 16 at 7:00 AMAnalysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)markets.businessinsider.com - April 10 at 12:46 PMFoghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliancesmarkets.businessinsider.com - April 10 at 12:46 PMFoghorn Therapeutics' (FHTX) Outperform Rating Reiterated at Wedbushmarketbeat.com - April 10 at 8:17 AMFoghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programsglobenewswire.com - April 9 at 4:30 PMFoghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - April 9 at 8:47 AMFoghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conferencefinance.yahoo.com - April 5 at 8:27 AMFoghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conferenceglobenewswire.com - April 5 at 7:00 AMFed commentary, jobless claims data: What to Watchfinance.yahoo.com - April 4 at 9:31 AMRaymond James & Associates Increases Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX)marketbeat.com - April 4 at 4:23 AMFoghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meetingglobenewswire.com - March 26 at 7:00 AMFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest Down 8.8% in Februarymarketbeat.com - March 19 at 8:39 PMCambridge biotech discloses it quietly laid off 28% of its staff last yearbizjournals.com - March 8 at 9:36 AMFHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 7 at 5:03 PMFoghorn Therapeutics: Q4 Earnings Insightsbenzinga.com - March 7 at 1:07 PMFoghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlookfinanznachrichten.de - March 7 at 8:07 AMFoghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlookglobenewswire.com - March 7 at 7:00 AMFoghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909globenewswire.com - March 5 at 4:48 PMFoghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conferencefinance.yahoo.com - February 28 at 9:41 AMFoghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 7:00 AMFoghorn Therapeutics Inc.thestreet.com - February 26 at 9:52 AMShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Rises By 16.2%marketbeat.com - February 16 at 5:25 PMFoghorn Therapeutics Inc (FHTX)investing.com - February 15 at 1:24 PMFoghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?finance.yahoo.com - February 12 at 9:44 AMAnalysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)markets.businessinsider.com - February 9 at 1:31 PMFoghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Developmentfinance.yahoo.com - February 9 at 1:31 PMFoghorn Therapeutics Releases New Investor Presentationmsn.com - February 9 at 8:29 AMWhy Foghorn Therapeutics (FHTX) Stock Is Exploding Highermsn.com - February 8 at 2:21 PMFoghorn says Eli Lilly picked lung cancer candidate for further studiesmsn.com - February 8 at 8:12 AMFoghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitorfinance.yahoo.com - February 8 at 8:12 AMRaymond James & Associates Purchases 235,237 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX)marketbeat.com - January 17 at 4:17 AMWith 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interestfinance.yahoo.com - January 11 at 9:34 AMPension plans at the largest companies in the U.S. reached 100% funding status in 2023, according to a WTW analysisfortune.com - January 4 at 9:34 AMFoghorn Therapeutics Announces CFO Departurefinance.yahoo.com - January 3 at 7:07 PMFoghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Whyfinance.yahoo.com - December 26 at 3:05 PMFoghorn Therapeutics Inc Ordinary Shares FHTXmorningstar.com - December 14 at 3:55 PMHow Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%finance.yahoo.com - December 11 at 12:45 PMFoghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meetingfinance.yahoo.com - December 1 at 9:09 AMFoghorn Therapeutics Stock (NASDAQ:FHTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 15 at 1:59 PMNews Flash: Analysts Just Made A Sizeable Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecastsfinance.yahoo.com - November 7 at 10:27 AMFoghorn Therapeutics Inc (FHTX) Reports Q3 2023 Financial Results and Corporate Updatesfinance.yahoo.com - November 3 at 10:27 AMWe Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefullyfinance.yahoo.com - November 1 at 7:28 AMFHTX Nov 2023 5.000 callfinance.yahoo.com - October 28 at 12:42 PMFoghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congressfinance.yahoo.com - October 13 at 8:38 AMFoghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conferencefinance.yahoo.com - October 4 at 8:13 AMFoghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLfinance.yahoo.com - August 31 at 8:04 AMFoghorn Therapeutics Inc. (NASDAQ:FHTX) Insider Samuel Agresta Sells 311,297 Sharesmarketbeat.com - August 18 at 4:15 PMFoghorn Therapeutics: Ifs, Buts, And Clinical Holdsmsn.com - August 16 at 9:17 PM Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… FHTX Media Mentions By Week FHTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼0.000.43▲Average Medical News Sentiment FHTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼11▲FHTX Articles Average Week Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: G1 Therapeutics News Today Immutep News Today Acrivon Therapeutics News Today Generation Bio News Today Merrimack Pharmaceuticals News Today Ovid Therapeutics News Today Prelude Therapeutics News Today Conduit Pharmaceuticals News Today Galectin Therapeutics News Today Aldeyra Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
